G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Lessons learned from EVOLVE for the planning of future global randomized trials in chronic kidney disease
Patrick S. Parfrey,Geoffrey A. Block,Ricardo Correa-Rotter,Tilman B. Drüeke,J. Floege,Charles A. Herzog,Gérard M. London,Kenneth W. Mahaffey,Sharon M. Moe,David C. Wheeler,Glenn M. Chertow +10 more
TL;DR: During planning, execution, analysis and reporting of the trial many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints, importance of age for optimal stratification at randomization and interpretation of the benefits to harms ratio for individual patients.
Journal ArticleDOI
Treatment of metabolic acidosis with an intestinal binder.
Shen Song,Glenn M. Chertow +1 more
Journal ArticleDOI
Lessons for Medicare Part D in the hemodialysis community
Anisa I Nayeem,Glenn M. Chertow +1 more
TL;DR: Examining the level of understanding and use of the temporary Medicare Prescription Drug Discount Card Program in the hemodialysis population can gain a better understanding of the potential long-term utilization for Medicare Part D.
Journal ArticleDOI
National Imaging Trends for Suspected Urinary Stone Disease in the Emergency Department.
Calyani Ganesan,Margaret Stedman,Sai Liu,Simon L. Conti,Glenn M. Chertow,John T. Leppert,Alan C. Pao +6 more
TL;DR: In this paper , the authors examined the use of an ultrasonography-first strategy for urinary stone disease in a cohort study and found that the strategy was effective in reducing the number of urinary stones.
Journal ArticleDOI
Prolonged Hospitalization Following Acute Respiratory Failure.
TL;DR: From 2004-2014, incidence and mortality decreased among patients with ARF and pLOS, and while per patient costs rose, percent of total cost of care remained stable, there is substantial variation in length-of-stay for patients withARF by US region, hospital teaching status and patient insurance coverage.